METASTATIC NON SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cells supercharged to fight advanced cancers
Disease control Recruiting nowThis study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Obsidian Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Lung cancer Patients' own immune cells could shrink tumors in new trial
Disease control Recruiting nowThis phase 2 trial tests a personalized therapy called LN-145, made from a patient's own tumor-fighting immune cells. Researchers take a sample of the tumor, grow the immune cells in a lab, and then infuse them back into the patient after a short course of chemotherapy. The goal …
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Electric field therapy device takes on metastatic lung cancer in major trial
Disease control Recruiting nowThis Phase 3 trial tests whether adding a wearable device that delivers electric fields (TTFields) to standard immunotherapy and chemotherapy improves survival in people with metastatic non-small cell lung cancer. About 734 participants who have not had prior treatment for their …
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New CAR t cell therapy targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis early-phase trial tests a new type of immunotherapy for people with a specific kind of advanced lung cancer (FRa-positive NSCLC). Researchers take a patient's own immune cells, engineer them to recognize and attack cancer cells, and deliver them directly into the chest cavit…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation plus immunotherapy may offer new hope for lung cancer patients
Disease control Recruiting nowThis study tests whether adding targeted radiation to immunotherapy can help control advanced non-small cell lung cancer better than standard chemotherapy. It is for patients whose cancer has worsened after previous immunotherapy. About 39 adults will be randomly assigned to one …
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental cell therapy targets multiple cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for hard-to-treat lung cancer: targeted drug plus immunotherapy tested
Disease control Recruiting nowThis study tests a drug called adagrasib, alone or with pembrolizumab (an immunotherapy), in people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the combination shrinks tumors and helps people live longer without t…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for rare lung cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New lung cancer combo aims to beat current standard
Disease control Recruiting nowThis study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could less be more? new study tests lower doses of cancer drug
Disease control Recruiting nowThis study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Lung cancer trial combines two treatments to outsmart resistance
Disease control Recruiting nowThis study compares the standard drug osimertinib alone versus osimertinib plus chemotherapy (carboplatin and pemetrexed) in people with metastatic EGFR-mutant lung cancer who still have detectable cancer DNA in their blood after starting osimertinib. The goal is to see if the co…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Lighter chemo, same punch? new combo aims to spare older lung cancer patients harsh side effects
Disease control Recruiting nowThis study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to sto…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for EGFR lung cancer: Dato-DXd combo tested in phase 3 trial
Disease control Recruiting nowThis Phase 3 trial is testing whether the drug Dato-DXd, given alone or with osimertinib, can help people with a specific type of advanced lung cancer (EGFR-mutated) that has stopped responding to osimertinib. About 744 participants will be randomly assigned to receive either the…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New targeted pill shows promise for tough lung cancer
Disease control Recruiting nowThis early-stage trial tests an experimental drug called BBO-8520 in 350 people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The drug is taken as a pill and aims to block cancer growth. The study will check for safety, side effects, and…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new drug called STC-15, either alone or combined with an immunotherapy drug (toripalimab), in people with advanced solid tumors or certain sarcomas. The study aims to check safety and whether the drugs shrink tumors. About 107 participants will be e…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radiation boost may extend life in lung cancer that has spread to a few spots
Disease control Recruiting nowThis phase 3 trial tests whether adding targeted radiation to all cancer spots (up to 5) improves survival in people with non-small cell lung cancer that has spread to a few places. Participants receive either standard maintenance therapy alone or standard therapy plus radiation.…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Tata Memorial Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:46 UTC
-
Breathing new life: rehab program tested for advanced lung cancer patients
Symptom relief Recruiting nowThis study tests whether a respiratory rehabilitation program—including exercise training, breathing exercises, and education—can improve quality of life for people with advanced non-small cell lung cancer who are on maintenance chemotherapy and immunotherapy. Researchers will co…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: NA • Sponsor: University Hospital, Brest • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Scientists investigate immune cells in lung cancer
Knowledge-focused Recruiting nowThis study looks at different types of neutrophils (a kind of immune cell) in the blood of people with lung cancer. Researchers want to see if certain neutrophil types are linked to tumor growth and resistance to immunotherapy. They will compare blood samples from 100 lung cancer…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Blood test may predict which lung cancer patients respond to immunotherapy
Knowledge-focused Recruiting nowThis study is testing whether a liquid biopsy (a blood test that looks for tumor DNA) can predict how well immunotherapy works in people with advanced lung cancer. Researchers will track changes in ctDNA levels from before treatment to six weeks after, and see if those changes ma…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: NA • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:14 UTC